3SBIO News

Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?

① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.

cls.cnMar 27 04:08 ET

Is the profit turning point starting to appear? The Hong Kong stock market's Innovative Drugs Sector is strengthening, and the annual reports show that multiple pharmaceutical companies are entering a period of performance harvest.

① The Innovative Drugs Sector in Hong Kong stocks has risen across the board, what Bullish factors are worth paying attention to? ② Annual reports show that multiple pharmaceutical companies have entered a performance harvest period, does this indicate that a profit turning point is approaching?

cls.cnMar 27 03:32 ET

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Acrivon Therapeutics, Inc. (ACRV) and 3SBio (OtherTRSBF)

TipRanksMar 26 08:10 ET · Ratings

3SBio's 2024 Profit Jumps 35%

MT NewswiresMar 26 05:19 ET

3SBio Inc.'s (HKG:1530) 42% Jump Shows Its Popularity With Investors

Simply Wall StMar 25 18:53 ET

3SBio Announces Final Dividend for 2024

TipRanksMar 25 18:07 ET

3SBIO (01530.HK) announced its annual performance, with R&D costs significantly increasing by approximately 66.9%. It is expected that from 2025, key new drugs will enter the commercialization stage each year.

Gelonghui, March 25th丨3SBIO (01530.HK) announced that for the year ending December 31, 2024, the company's revenue increased by 1,292.1 million RMB or 16.5% to 9,108 million RMB. Gross profit increased by 1,186.8 million RMB or 17.9% to 7,828.4 million RMB, with a gross margin of 86.0%. The profit attributable to equity holders of the parent company increased by 541.1 million RMB or 34.9% to 2,090.3 million RMB. The adjusted operating profit attributable to equity holders of the parent company increased by 366.

Gelonghui FinanceMar 25 08:21 ET

Express News | 3Sbio - Final Dividend of HKD25 Cents per Share for Year

ReutersMar 25 07:56 ET

Express News | 3Sbio FY Basic EPS RMB 0.86

ReutersMar 25 07:56 ET

Express News | 3Sbio FY Adjusted Ebitda RMB 3,402.3 Million

ReutersMar 25 07:56 ET

Express News | 3Sbio FY Revenue RMB 9,108 Million

ReutersMar 25 07:56 ET

Express News | 3Sbio FY Ebitda RMB 3,173.8 Million

ReutersMar 25 07:56 ET

Express News | 3Sbio FY Gross Profit RMB 7,828.4 Million

ReutersMar 25 07:56 ET

Express News | 3Sbio FY Gross Margin 86%

ReutersMar 25 07:56 ET

3SBIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

HKEXMar 25 07:55 ET · Announcements

The Hong Kong stock market is restructuring the value of pharmaceuticals! Hengrui Medicine has received a premium binding from AstraZeneca, and the stock price once rose over 20%.

① Does the offshore strategy mean that "technology platform premium + international certification" is replacing the traditional PE valuation method as the core logic for valuing Innovative Drugs companies? ② With JACOBIO-B narrowing its annual loss by 56.6% through its core product Galidesivir, can it be inferred that China’s Innovative Drugs companies have broken through the industry curse of "burning money on R&D - ongoing losses"?

cls.cnMar 23 22:56 ET

How strong are the Hong Kong pharmaceutical stocks right now? The Innovative Drugs Index has risen over 30% this year, reaching a near 16-month high.

① The Innovative Drugs Index in the Hong Kong stock market has increased by over 30% this year; why can it compete with Technology stocks? ② There has been a "small peak" in the commercialization of individual stocks; how do Institutions perceive the future market direction?

cls.cnMar 20 04:36 ET

Is the CRO Concept "Return of the King"? WuXi AppTec aggressively attacks, leading stocks celebrate after performance!

Release the signal?!

Gelonghui FinanceMar 18 01:42 ET

GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.

GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.

Zhitong FinanceMar 16 21:18 ET

Is the breakthrough path all in AI? Chain pharmacies are facing a wave of closures and an era of low profits.

① In 2024, particularly in the second half of the year, chain pharmacies will face a large-scale wave of closures, and leading chain pharmacies will generally enter a low-profit era. ② AI is also being assigned higher expectations in helping pharmacies reduce costs and increase efficiency. ③ Publicly available large models, due to a lack of support from vertical domain data, are still insufficient to support the actual Business Operation of pharmacies.

cls.cnMar 16 02:09 ET